Nuvalent (NUVL) Preferred Stock Liabilities (2020 - 2021)
Nuvalent's (NUVL) quarterly Preferred Stock Liabilities came in at $185.4 million in Q2 2021, up 641.36% YoY from $25.0 million in Q2 2020, and up 265.27% on a QoQ basis from $50.8 million in Q1 2021.
Nuvalent (NUVL) Preferred Stock Liabilities (2020 - 2021) Analysis & Trends
Nuvalent (NUVL) has 2 years of Preferred Stock Liabilities data on file, last reported at $185.4 million in Q2 2021.
- Quarterly Preferred Stock Liabilities rose 641.36% year-over-year to $185.4 million in Q2 2021, while the trailing twelve-month figure through Jun 2021 was $185.4 million (up 641.36% YoY) and the FY2020 annual result came in at $35.4 million, changed N/A from the prior year.
- Preferred Stock Liabilities advanced to $185.4 million in Q2 2021, from $50.8 million in the prior quarter.
- In the past five years, Preferred Stock Liabilities ranged from a high of $185.4 million in Q2 2021 to a low of $25.0 million in Q2 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Nuvalent | 9.10 Bn | 9.10 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | 185.41 Mn |
| Mar 31, 2021 | 50.76 Mn |
| Dec 31, 2020 | 35.35 Mn |
| Sep 30, 2020 | 35.35 Mn |
| Jun 30, 2020 | 25.01 Mn |